Minocycline hydrochloride ER is under clinical development by Promius Pharma and currently in Pre-Registration for Rosacea. According to GlobalData, Pre-Registration drugs for Rosacea have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Minocycline hydrochloride ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Minocycline hydrochloride ER overview

Minocycline hydrochloride is under development for the treatment of rosacea. The drug candidate is a small molecule and acts by targeting 16S ribosomal subunit. The drug candidate is administered through oral route in the form of an extended release and modified release capsule.

Promius Pharma overview

Promius Pharma, a subsidiary of Dr. Reddy’s Laboratories Ltd, is a designer of personal and practical health care solutions that provides dermatology and neurology products. The company provides dermatology and neurology products. Its products include clocortolone pivalate, promiseb topical cream, betamethasone dipropionate, triamcinolone acetonide ointment USP and sumatriptan injection. Promius Pharma’s promiseb topical cream is used for the treatment of seborrheic dermatitis. The company has operational research and development laboratories for product ideation, product formulation, and analytics and testing. Promius Pharma is headquartered in Princeton, New Jersey, the US.

For a complete picture of Minocycline hydrochloride ER’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.